Platelet Thrombin Receptor Inhibition: Preserved Hemostasis Without Thrombosis?

Findings from a phase II study suggest that a novel antiplatelet agent is safe, even when combined with aspirin and clopidogrel.

New antithrombotic strategies are required to reduce cardiovascular complications after percutaneous coronary intervention without increasing bleeding risk. The highly selective antagonist SCH 530348 inhibits the platelet thrombin receptor PAR-1; its use represents a novel approach to blocking thrombin-mediated platelet activation.

In a manufacturer-sponsored, multicenter study, researchers randomly assigned 1030 patients to receive oral SCH 530348 (10 mg, 20 mg, or 40 mg) or matching placebo at least 1 hour before undergoing elective angiography with intent to perform PCI. Patients who subsequently underwent PCI received a maintenance dose of SCH 530348 (0.5 mg, 1.0 mg, or 2.5 mg daily) or placebo for 60 days. All patients received aspirin …

Reviewing Author

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)